

Cholesterol and Recurrent Events (CARE) Publications

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—a combined analysis of three large-scale randomized trials: Long-term Intervention with pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). *Am J Cardiol* 1995;76:899-905.

Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. *Circulation* 1998;98:2513-2519.

Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JMO, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA. Predictors of late development of heart failure in stable survivors of myocardial infarction: The CARE study. *J Am Coll Cardiol* 2003; 42:1446-53.

Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. *Ann Intern Med* 1998;129:681-689.

Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau JL, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. *J Am Coll Cardiol* 1998;32:140-6.

Moye LA, Davis BR, Sacks F, Cole T, Brown L, Hawkins CM. Decision rules for predicting future lipid values in screening for a cholesterol reduction clinical trial. *Control Clin Trials* 1996;17:536-546.

Pfeffer MA, Sacks FM, Moye LA, East C, Goldman S, Nash DT, Rouleau JR, Rouleau JL, Sussex BA, Theroux P, Vanden Belt RJ, Braunwald E. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol and Recurrent Events. *J Am Coll Cardiol* 1999;33:125-130.

Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, et al. Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. *Am J Cardiol* 1995;76:98C-106C.

Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moya LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. *Circulation* 1999;99:216-223.

Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moya LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. *Circulation* 1998;98:839-44.

Sacks FM, Moya LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. *Circulation* 1998;97:1446-52.

Sacks FM, Pfeffer MA, Moya LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;335:1001-1009.

Sacks FM, Rouleau JL, Moya LA, Pfeffer MA, Warnica JW, Arnold JM, Nash DT, Brown LE, Sestier F, Rutherford J, et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. *Am J Cardiol* 1995;75:621-623.

Sacks FM, Pfeffer MA, Moya' L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial [Published erratum appears in *Am J Cardiol* 1992;69:574]. *Am J Cardiol* 1991;68:1436-1446.

Wilt TJ, Davis BR, Meyers DG, Rouleau JL, Sacks FM. Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dl: baseline results from the Cholesterol and Recurrent Events (CARE) Study. *Angiology* 1996;47:533-541.